Ang Lifesciences India Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of ANG Lifesciences India Ltd is ₹ 27.38 as of 05 May 15:30 . The P/E Ratio of ANG Lifesciences India Ltd changed from 6 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of ANG Lifesciences India Ltd changed from ₹ 243.2 crore on March 2022 to ₹ 29.67 crore on March 2025 . This represents a CAGR of -40.90% over 4 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of ANG Lifesciences India Ltd for the Dec '25 is ₹ 18.89 crore as compare to the Sep '25 revenue of ₹ 26.18 crore. This represent the decline of -27.85% The revenue of Medicamen Biotech Ltd for the Dec '25 is ₹ 47.44 crore as compare to the Sep '25 revenue of ₹ 47.54 crore. This represent the decline of -0.21% The ebitda of ANG Lifesciences India Ltd for the Dec '25 is ₹ -2.53 crore as compare to the Sep '25 ebitda of ₹ 0.2 crore. This represent the decline of -1365% The ebitda of Medicamen Biotech Ltd for the Dec '25 is ₹ 4.91 crore as compare to the Sep '25 ebitda of ₹ 5.53 crore. This represent the decline of -11.21% The net profit of ANG Lifesciences India Ltd changed from ₹ -3.07 crore to ₹ -4.75 crore over 7 quarters. This represents a CAGR of 28.33% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 1.63 crore over 7 quarters. This represents a CAGR of 50.19% The Dividend Payout of ANG Lifesciences India Ltd changed from 2.61 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About ANG Lifesciences India Ltd

ANG Lifesciences India Limited was originally incorporated as a Private Limited Company with the name 'ANG Lifesciences India Private Limited' on June 14, 2006.
On conversion into Public Limited Company, the name was changed to ANG Lifesciences India Limited on March 02, 2010.
The Company further converted into Private Limited Company and the name of the Company was changed to 'ANG Lifesciences India Private Limited' on September 22, 2010.
Subsequently, on conversion into Public Limited Company, the name again changed to 'ANG Lifesciences India Limited' on May 18, 2016. The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of Sterile Dry Powder Injection Vials.
In 2008-09, the Company started its commercial production.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of ANG Lifesciences India Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, ANG Lifesciences India Ltd or Medicamen Biotech Ltd?

Market cap of ANG Lifesciences India Ltd is 35 Cr while Market cap of Medicamen Biotech Ltd is 379 Cr

What are the key factors driving the stock performance of ANG Lifesciences India Ltd and Medicamen Biotech Ltd?

The stock performance of ANG Lifesciences India Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ANG Lifesciences India Ltd and Medicamen Biotech Ltd?

As of May 5, 2026, the ANG Lifesciences India Ltd stock price is INR ₹27.38. On the other hand, Medicamen Biotech Ltd stock price is INR ₹280.1.

How do dividend payouts of ANG Lifesciences India Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of ANG Lifesciences India Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.